YMTX
Income statement / Annual
Last year (2024), Yumanity Therapeutics, Inc.'s total revenue was $0.00,
a decrease of 100.00% from the previous year.
In 2024, Yumanity Therapeutics, Inc.'s net income was -$17.13 M.
See Yumanity Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$0.00 |
$5.44 M |
$1.95 M |
$9.09 M |
$10.49 M |
$5.00 M |
$2.84 M |
$5.34 M |
$8.38 M |
$4.31 M |
| Cost of Revenue |
$0.00
|
$9.00 K
|
$734.00 K
|
$669.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$5.43 M
|
$1.22 M
|
$8.42 M
|
$10.49 M
|
$5.00 M
|
$2.84 M
|
$5.34 M
|
$8.38 M
|
$4.31 M
|
| Gross Profit Ratio |
0
|
1
|
0.62
|
0.93
|
1
|
1
|
1
|
1
|
1
|
1
|
| Research and Development Expenses |
$5.39 M
|
$9.02 M
|
$34.79 M
|
$15.56 M
|
$9.22 M
|
$52.32 M
|
$50.31 M
|
$53.65 M
|
$33.96 M
|
$22.52 M
|
| General & Administrative Expenses |
$8.15 M
|
$12.14 M
|
$8.70 M
|
$4.62 M
|
$4.39 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$8.15 M
|
$12.14 M
|
$8.70 M
|
$4.62 M
|
$4.39 M
|
$12.42 M
|
$13.93 M
|
$10.26 M
|
$11.57 M
|
$6.05 M
|
| Other Expenses |
$0.00
|
$0.00
|
-$18.53 M
|
-$1.15 M
|
$865.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$13.53 M
|
$21.16 M
|
$43.48 M
|
$20.18 M
|
$13.60 M
|
$64.74 M
|
$64.24 M
|
$63.91 M
|
$45.53 M
|
$28.57 M
|
| Cost And Expenses |
$0.00
|
$21.17 M
|
$43.48 M
|
$20.18 M
|
$13.60 M
|
$66.15 M
|
$66.02 M
|
$65.31 M
|
$45.84 M
|
$28.85 M
|
| Interest Income |
$111.00 K
|
$325.00 K
|
$3.74 M
|
$1.29 M
|
$4.96 M
|
$1.09 M
|
$872.00 K
|
$641.00 K
|
$246.00 K
|
$0.00
|
| Interest Expense |
$138.00 K
|
$337.00 K
|
$3.74 M
|
$1.29 M
|
$4.96 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$599.00 K
|
| Depreciation & Amortization |
$0.00
|
$9.00 K
|
$734.00 K
|
$669.00 K
|
$3.27 M
|
$1.41 M
|
$1.78 M
|
$1.40 M
|
$306.00 K
|
$272.00 K
|
| EBITDA |
-$13.53 M |
-$15.71 M |
-$41.53 M |
-$10.42 M |
-$2.96 M |
-$59.74 M |
-$61.40 M |
-$58.57 M |
-$37.15 M |
-$24.26 M |
| EBITDA Ratio |
0
|
-2.89
|
-21.27
|
-1.15
|
-0.28
|
-11.95
|
-21.62
|
-10.97
|
-4.43
|
-5.63
|
| Operating Income Ratio |
0
|
-2.89
|
-21.27
|
-1.22
|
-0.3
|
-12.23
|
-22.25
|
-11.23
|
-4.47
|
-5.69
|
| Total Other Income/Expenses Net |
-$3.60 M
|
$1.65 M
|
-$21.92 M
|
-$724.00 K
|
-$4.00 M
|
$2.03 M
|
$1.35 M
|
$541.00 K
|
$223.00 K
|
-$506.00 K
|
| Income Before Tax |
-$17.13 M
|
-$14.08 M
|
-$63.45 M
|
-$11.82 M
|
-$7.11 M
|
-$59.13 M
|
-$61.83 M
|
-$59.43 M
|
-$37.23 M
|
-$25.04 M
|
| Income Before Tax Ratio |
0
|
-2.59
|
-32.49
|
-1.3
|
-0.68
|
-11.83
|
-21.77
|
-11.13
|
-4.44
|
-5.81
|
| Income Tax Expense |
$0.00
|
$0.00
|
-$386.00 K
|
$143.00 K
|
$6.77 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$17.13 M
|
-$14.10 M
|
-$63.07 M
|
-$11.96 M
|
-$13.88 M
|
-$59.13 M
|
-$61.83 M
|
-$59.43 M
|
-$37.23 M
|
-$25.04 M
|
| Net Income Ratio |
0
|
-2.59
|
-32.29
|
-1.32
|
-1.32
|
-11.83
|
-21.77
|
-11.13
|
-4.44
|
-5.81
|
| EPS |
-1.42 |
-1.28 |
-12.8 |
-8.14 |
-41.26 |
-161.86 |
-224.87 |
-327.48 |
-277.86 |
-140.85 |
| EPS Diluted |
-1.42 |
-1.28 |
-12.8 |
-8.14 |
-41.26 |
-161.86 |
-224.87 |
-327.48 |
-277.86 |
-140.85 |
| Weighted Average Shares Out |
$12.10 M
|
$11.05 M
|
$4.93 M
|
$1.47 M
|
$336.31 K
|
$365.28 K
|
$274.97 K
|
$181.49 K
|
$134.00 K
|
$177.78 K
|
| Weighted Average Shares Out Diluted |
$12.10 M
|
$11.05 M
|
$4.93 M
|
$1.47 M
|
$336.31 K
|
$365.28 K
|
$274.97 K
|
$181.49 K
|
$134.00 K
|
$177.78 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
